Alnylam Pharmaceuticals, Inc. (ALNY) Financial Ratios
24 years of historical data (2002–2025) · Healthcare · Biotechnology
EV/EBITDA
71.87
↓-25% vs avg
5yr avg: 95.43
30Y Low95.4·High95.4
P/FCF
↓
86.87
↓-75% vs avg
5yr avg: 342.54
30Y Low6.0·High115.1
P/B Ratio
↑
51.71
↓-72% vs avg
5yr avg: 183.25
30Y Low1.9·High67.9
ROE
↑
73.3%
↓+130% vs avg
5yr avg: -243.4%
30Y Low-415%·High73%
Debt/EBITDA
2.29
+0% vs avg
5yr avg: 2.29
30Y Low2.3·High2.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ALNY Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Alnylam Pharmaceuticals, Inc. trades at 130.0x earnings, 24% below its 5-year average of 170.7x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 487%. On a free-cash-flow basis, the stock trades at 86.9x P/FCF, 75% below the 5-year average of 342.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $40.4B | $53.6B | $30.0B | $23.9B | $28.9B | $20.1B | $14.9B | $12.6B | $7.3B | $11.5B | $3.2B |
| Enterprise Value | $40.0B | $53.2B | $31.8B | $24.4B | $29.4B | $20.3B | $15.0B | $12.3B | $6.9B | $10.9B | $3.2B |
| P/E Ratio → | 130.04 | 170.67 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 10.89 | 14.42 | 13.36 | 13.08 | 27.88 | 23.79 | 30.32 | 57.26 | 97.91 | 127.96 | 67.96 |
| P/B Ratio | 51.71 | 67.86 | 447.73 | — | — | 34.15 | 14.71 | 8.75 | 5.63 | 6.51 | 3.48 |
| P/FCF | 86.87 | 115.08 | — | 569.99 | — | — | — | — | — | — | — |
| P/OCF | 77.14 | 102.19 | — | 229.54 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ALNY EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Alnylam Pharmaceuticals, Inc.'s enterprise value stands at 71.9x EBITDA, 25% below its 5-year average of 95.4x. The Healthcare sector median is 14.1x, placing the stock at a 408% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.32 | 14.15 | 13.35 | 28.31 | 24.00 | 30.37 | 56.16 | 92.70 | 121.11 | 67.03 |
| EV / EBITDA | 71.87 | 95.43 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 79.85 | 106.02 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 114.27 | — | 581.74 | — | — | — | — | — | — | — |
ALNY Profitability
Margins and return-on-capital ratios measuring operating efficiency
Alnylam Pharmaceuticals, Inc. earns an operating margin of 13.5%. Operating margins have expanded from -15.4% to 13.5% over the past 3 years, signaling improving operational efficiency. Return on equity of 73.3% is exceptionally high. ROIC of 33.4% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.8% | 81.8% | 85.6% | 83.0% | 83.7% | 83.4% | 84.2% | 88.6% | 97.6% | 85.1% | 100.0% |
| Operating Margin | 13.5% | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | -556.2% | -900.3% |
| Net Profit Margin | 8.4% | 8.4% | -12.4% | -24.1% | -109.0% | -101.0% | -174.1% | -403.2% | -1016.6% | -545.9% | -869.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 73.3% | 73.3% | -414.6% | — | -526.1% | -106.3% | -69.9% | -64.7% | -49.6% | -36.5% | -37.5% |
| ROA | 6.8% | 6.8% | -6.9% | -11.9% | -31.5% | -24.2% | -29.6% | -44.6% | -42.7% | -30.1% | -31.0% |
| ROIC | 33.4% | 33.4% | -12.5% | -74.6% | -110.9% | -58.8% | -55.6% | -66.9% | -59.2% | -37.0% | -32.5% |
| ROCE | 15.3% | 15.3% | -6.0% | -10.0% | -27.4% | -24.6% | -34.1% | -54.7% | -50.2% | -33.5% | -34.6% |
ALNY Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Alnylam Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 2.3x, which is manageable (29% below the sector average of 3.3x). The company holds a net cash position — cash of $1.7B exceeds total debt of $1.3B, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of just 2.0x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.62 | 1.62 | 40.89 | — | — | 1.70 | 0.51 | 0.21 | 0.02 | 0.02 | 0.16 |
| Debt / EBITDA | 2.29 | 2.29 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.48 | 26.49 | — | — | 0.30 | 0.02 | -0.17 | -0.30 | -0.35 | -0.05 |
| Net Debt / EBITDA | -0.68 | -0.68 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.81 | — | 11.75 | — | — | — | — | — | — | — |
| Interest Coverage | 1.99 | 1.99 | -1.66 | -2.58 | -6.23 | -4.96 | -9.13 | — | — | — | — |
Net cash position: cash ($1.7B) exceeds total debt ($1.3B)
ALNY Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Alnylam Pharmaceuticals, Inc.'s current ratio of 2.76x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.08x to 2.76x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.76 | 2.76 | 2.78 | 3.08 | 3.51 | 4.04 | 4.47 | 4.87 | 6.69 | 12.23 | 5.10 |
| Quick Ratio | 2.71 | 2.71 | 2.71 | 2.99 | 3.34 | 3.91 | 4.34 | 4.71 | 6.56 | 12.23 | 5.10 |
| Cash Ratio | 1.98 | 1.98 | 2.27 | 2.52 | 2.86 | 3.50 | 3.20 | 4.36 | 6.04 | 11.72 | 4.76 |
| Asset Turnover | — | 0.75 | 0.53 | 0.48 | 0.29 | 0.23 | 0.14 | 0.09 | 0.05 | 0.05 | 0.04 |
| Inventory Turnover | 8.19 | 8.19 | 4.12 | 3.48 | 1.31 | 1.62 | 1.04 | 0.44 | 0.07 | — | — |
| Days Sales Outstanding | — | 76.42 | 65.80 | 65.44 | 83.72 | 85.85 | 446.14 | 71.44 | 91.41 | 138.03 | 180.60 |
ALNY Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Alnylam Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.8% | 0.6% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.2% | 0.9% | — | 0.2% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $135M | $128M | $125M | $122M | $118M | $115M | $109M | $101M | $91M | $86M |
Peer Comparison
Compare ALNY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ALNYYou | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IONS | $13B | -32.3 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ARWR | $11B | -6486.9 | 91.8 | 70.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 MRNA | $19B | -6.7 | — | — | 55.3% | -158.1% | -28.9% | -26.1% | — |
 CRSP | $5B | -8.5 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 REGN | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 BIIB | $28B | 21.6 | 11.4 | 13.7 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 BMRN | $11B | 30.3 | 16.0 | 14.5 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 24 years · Updated daily
Full ALNY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ALNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALNY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALNY vs IONS
Side-by-side business, growth, and profitability comparison vs Ionis Pharmaceuticals, Inc..
Start ComparisonALNY — Frequently Asked Questions
Quick answers to the most common questions about buying ALNY stock.
What is Alnylam Pharmaceuticals, Inc.'s P/E ratio?
Alnylam Pharmaceuticals, Inc.'s current P/E ratio is 130.0x. The historical average is 170.7x.
What is Alnylam Pharmaceuticals, Inc.'s EV/EBITDA?
Alnylam Pharmaceuticals, Inc.'s current EV/EBITDA is 71.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 95.4x.
What is Alnylam Pharmaceuticals, Inc.'s ROE?
Alnylam Pharmaceuticals, Inc.'s return on equity (ROE) is 73.3%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -75.5%.
Is ALNY stock overvalued?
Based on historical data, Alnylam Pharmaceuticals, Inc. is trading at a P/E of 130.0x. Compare with industry peers and growth rates for a complete picture.
What are Alnylam Pharmaceuticals, Inc.'s profit margins?
Alnylam Pharmaceuticals, Inc. has 81.8% gross margin and 13.5% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Alnylam Pharmaceuticals, Inc. have?
Alnylam Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.